Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

A clinical scoring system for early onset (neonatal) Marfan syndrome

  • Yuri A. Zarate
  • , Shaine A. Morris
  • , Anna Blackshare
  • , Claudia A. Algaze
  • , Brynn S. Connor
  • , Andrew J. Kim
  • , Katherine E. Yutzey
  • , Erin M. Miller
  • , Kathryn Nicole Weaver
  • , Ronnie Thomas Collins

Producción científica: Articlerevisión exhaustiva

10 Citas (Scopus)

Resumen

Purpose: This study aimed to develop objective diagnostic criteria for early onset Marfan syndrome (eoMFS) to facilitate early diagnosis and timely interventions. Methods: On the basis of an extensive literature review and the responses from a survey distributed among providers with expertise in the diagnosis and management of eoMFS, we developed an age-based, diagnostic scoring system encompassing 10 features common to eoMFS (9 clinical + 1 laboratory) and divided them into cardiac, systemic, and FBN1 (on the basis of the location of the pathogenic FBN1 variant) scores. Results: In total, 77 individuals with eoMFS (13 newly reported) and 49 individuals diagnosed with classical Marfan syndrome during early childhood were used to validate the criteria. Median cardiac (8 vs 0, P <.001), systemic (11 vs 3, P <.001), FBN1 (5 vs 0, P <.001), and total (23 vs 4, P <.001) scores were significantly higher in individuals with eoMFS than in those without. A proposed clinical score (cardiac + systemic) cutoff of ≥14 points showed excellent sensitivity (100%), specificity (92%), and reliability (correctly classified = 94%). Conclusion: Distinct from classical Marfan syndrome in phenotype and morbidity, eoMFS can be diagnosed clinically using an objective scoring system encompassing the typical physical features and cardiac disease manifestations. Although genetic testing can be suggestive of eoMFS, genetic testing alone is insufficient for diagnosis.

Idioma originalEnglish
Páginas (desde-hasta)1503-1511
Número de páginas9
PublicaciónGenetics in Medicine
Volumen24
N.º7
DOI
EstadoPublished - jul 2022

Nota bibliográfica

Publisher Copyright:
© 2022 American College of Medical Genetics and Genomics

Financiación

The authors would like to thank the providers who responded to the initial survey. Support for REDCap was made possible through the University of Arkansas for Medical Sciences Translational Research Institute (NCATS/NIH UL1 RR029884). Conceptualization: Y.A.Z. S.A.M. A.B. R.T.C.; Formal Analysis: Y.A.Z. A.B. C.A.A. B.S.C.; Investigation: Y.A.Z. S.A.M. A.B. A.J.K. K.E.Y. E.M.M. K.N.W. R.T.C.; Resources: Y.A.Z. C.A.A. B.S.C.; Writing-original draft: Y.A.Z. R.T.C.; Writing-review and editing: Y.A.Z. S.A.M. C.A.A. K.E.Y. E.M.M. K.N.W. R.T.C. Approval for the review and reporting of these cases was given by the Institutional Review Board of the University of Arkansas for Medical Sciences. Data from the survey distributed to the providers were anonymized. Written informed consent was obtained from individual ID#62 for the scientific use of photo documentation.

FinanciadoresNúmero del financiador
National Institutes of Health (NIH)UL1 RR029884
National Center for Advancing Translational Sciences (NCATS)
University of Arkansas for Medical Sciences
Translational Research Institute, University of Arkansas for Medical Sciences

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • Genetics(clinical)

    Huella

    Profundice en los temas de investigación de 'A clinical scoring system for early onset (neonatal) Marfan syndrome'. En conjunto forman una huella única.

    Citar esto